Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immatics NV (NQ: IMTX ) 10.86 +0.51 (+4.93%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Immatics NV Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 October 04, 2024 From https://immatics.com/ Via GlobeNewswire Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update September 16, 2024 From https://immatics.com/ Via GlobeNewswire Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024 September 06, 2024 From https://immatics.com/ Via GlobeNewswire Immatics Announces Second Quarter 2024 Financial Results and Business Update August 13, 2024 From https://immatics.com/ Via GlobeNewswire Immatics Appoints Alise Reicin to Board of Directors July 31, 2024 From https://immatics.com/ Via GlobeNewswire Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024 July 18, 2024 From https://immatics.com/ Via GlobeNewswire Immatics Announces First Quarter 2024 Financial Results and Business Update May 14, 2024 From https://immatics.com/ Via GlobeNewswire Immatics Announces Full Year 2023 Financial Results and Corporate Update March 21, 2024 From https://immatics.com/ Via GlobeNewswire Immatics Announces Pricing of $175 Million Public Offering January 17, 2024 From https://immatics.com/ Via GlobeNewswire Immatics Announces Proposed Public Offering January 17, 2024 From https://immatics.com/ Via GlobeNewswire Immatics Announces Third Quarter 2023 Financial Results and Business Update November 14, 2023 From https://immatics.com/ Via GlobeNewswire Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial November 08, 2023 From https://immatics.com/ Via GlobeNewswire Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy October 24, 2023 From https://immatics.com/ Via GlobeNewswire Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics September 11, 2023 Via ACCESSWIRE Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics September 11, 2023 From https://immatics.com/ Via GlobeNewswire Immatics Announces Second Quarter 2023 Financial Results and Business Update August 17, 2023 From https://immatics.com/ Via GlobeNewswire Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors August 10, 2023 From https://immatics.com/ Via GlobeNewswire Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb July 24, 2023 From https://immatics.com/ Via GlobeNewswire Immatics Announces First Quarter 2023 Financial Results and Business Update May 16, 2023 From https://immatics.com/ Via GlobeNewswire Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME May 02, 2023 From https://immatics.com/ Via GlobeNewswire Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration May 01, 2023 From https://immatics.com/ Via GlobeNewswire Immatics Announces Full Year 2022 Financial Results and Corporate Update March 21, 2023 From https://immatics.com/ Via GlobeNewswire Immatics Announces Third Quarter 2022 Financial Results and Business Update November 17, 2022 From https://immatics.com/ Via GlobeNewswire Immatics Announces $110 Million Underwritten Offering of Ordinary Shares October 10, 2022 From https://immatics.com/ Via GlobeNewswire Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME October 10, 2022 From https://immatics.com/ Via GlobeNewswire Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs June 02, 2022 From Bristol Myers Squibb Via Business Wire Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401 December 14, 2021 From Bristol Myers Squibb Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.